Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66045.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10). doi: 10.1073/pnas.2011653118.
Vaccine-based elicitation of broadly neutralizing antibodies holds great promise for preventing HIV-1 transmission. However, the key biophysical markers of improved antibody recognition remain uncertain in the diverse landscape of potential antibody mutation pathways, and a more complete understanding of anti-HIV-1 fusion peptide (FP) antibody development will accelerate rational vaccine designs. Here we survey the mutational landscape of the vaccine-elicited anti-FP antibody, vFP16.02, to determine the genetic, structural, and functional features associated with antibody improvement or fitness. Using site-saturation mutagenesis and yeast display functional screening, we found that 1% of possible single mutations improved HIV-1 envelope trimer (Env) affinity, but generally comprised rare somatic hypermutations that may not arise frequently in vivo. We observed that many single mutations in the vFP16.02 Fab could enhance affinity >1,000-fold against soluble FP, although affinity improvements against the HIV-1 trimer were more measured and rare. The most potent variants enhanced affinity to both soluble FP and Env, had mutations concentrated in antibody framework regions, and achieved up to 37% neutralization breadth compared to 28% neutralization of the template antibody. Altered heavy- and light-chain interface angles and conformational dynamics, as well as reduced Fab thermal stability, were associated with improved HIV-1 neutralization breadth and potency. We also observed parallel sets of mutations that enhanced viral neutralization through similar structural mechanisms. These data provide a quantitative understanding of the mutational landscape for vaccine-elicited FP-directed broadly neutralizing antibody and demonstrate that numerous antigen-distal framework mutations can improve antibody function by enhancing affinity simultaneously toward HIV-1 Env and FP.
基于疫苗的广泛中和抗体的诱导在预防 HIV-1 传播方面具有很大的前景。然而,在潜在抗体突变途径的多样化背景下,改善抗体识别的关键生物物理标记仍然不确定,对 HIV-1 融合肽 (FP) 抗体的更全面了解将加速合理疫苗设计。在这里,我们调查了疫苗诱导的抗-FP 抗体 vFP16.02 的突变景观,以确定与抗体改善或适应性相关的遗传、结构和功能特征。通过位点饱和诱变和酵母展示功能筛选,我们发现 1%的可能单突变可提高 HIV-1 包膜三聚体 (Env) 的亲和力,但通常包含罕见的体细胞超突变,这些突变在体内可能不会经常发生。我们观察到,vFP16.02 Fab 中的许多单突变可以将对可溶性 FP 的亲和力提高 1000 倍以上,尽管对 HIV-1 三聚体的亲和力提高更为显著且罕见。最有效的变体提高了对可溶性 FP 和 Env 的亲和力,突变集中在抗体框架区域,与模板抗体相比,达到了 37%的中和广度,而中和广度为 28%。重链和轻链界面角度和构象动力学的改变以及 Fab 热稳定性的降低与提高 HIV-1 中和广度和效力有关。我们还观察到了通过类似结构机制增强病毒中和作用的并行突变集。这些数据提供了对疫苗诱导的 FP 定向广泛中和抗体的突变景观的定量理解,并表明许多抗原远侧框架突变可以通过同时提高对 HIV-1 Env 和 FP 的亲和力来改善抗体功能。